Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70470 ↗At a glance
Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2026. Written by Anupam Kumar Singh and 12 co-authors. Institution: Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Major MEDLINE topics: Hepatitis B Vaccines, Inflammatory Bowel Diseases, Hepatitis B, Immunogenicity, Vaccine. 48 references.
Abstract (original language)
Background
Immunogenic response to hepatitis B virus (HBV) vaccine in patients with inflammatory bowel disease (IBD) is variable and often suboptimal.
Aim
To compare the immunogenicity of standard‐dose (20 μg) vs. double‐dose (40 μg) HBV vaccination in patients with IBD.
Methods
We randomised patients with IBD 1:1 to receive standard‐ or double‐dose HBV vaccine at 0, 1 and 6 months. Anti‐HBs titres were measured 1 month after the third dose. The primary outcome was an adequate immune response (AIR; anti‐HBs titre > 10 IU/L). Secondary outcomes included an effective immune response (EIR; anti‐HBs titre > 100 IU/L) and seroconversion stratified by disease activity.
Results
We randomised 45 patients to the standard‐dose and 43 to the double‐dose. Overall, 63 patients (71.6%) achieved AIR, and 51 (57.9%) achieved EIR. Both AIR (88.4% vs. 55.6%, p = 0.001) and EIR (69.8% vs. 46.7%, p = 0.028) rates were significantly higher with the double‐dose. Among patients receiving immunosuppressive therapy, double‐dose vaccination demonstrated significantly higher AIR (87.5% vs. 45.2%, p < 0.001) and EIR (65.6% vs. 35.5%, p = 0.017), while differences were not significant in those without immunosuppression. On multivariable analysis, predictors of AIR included double‐dose vaccination (odds ratio [OR] 11.63; 95% confidence interval [CI] 2.63–51.46) and anti‐TNFs (OR 0.03; 95% CI 0.002–0.6). Double‐dose vaccination was also associated with higher odds of achieving EIR (OR 3.52; 95% CI 1.04–11.92).
Conclusions
Double‐dose HBV vaccination significantly improved AIR and EIR over standard‐dose. These findings support a double‐dose strategy to optimize seroconversion in patients with IBD, especially those receiving immunosuppressive therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Gastroenterology, All India Institute of Medical Science, Jodhpur, Rajasthan, India.
- Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID profiles: Anupam Kumar Singh, Vaneet Jearth, Chhagan Lal Birda, Usha Dutta
Cite
APA
Singh, A. K., Soni, R. K., Jearth, V., Yadav, A. I., Birda, C. L., Chatterjee, A., Shah, J., Mohindra, R., Patil, A. N., Suri, V., Sharma, V., Sharma, A. K., & Dutta, U. (2026). Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70470
Vancouver
Singh AK, Soni RK, Jearth V, Yadav AI, Birda CL, Chatterjee A, et al. Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70470
BibTeX
@article{Singh2026,
author = {Singh, Anupam Kumar and Soni, Roop Kishor and Jearth, Vaneet and Yadav, Ashutosh Ishan and Birda, Chhagan Lal and Chatterjee, Abhirup and Shah, Jimil and Mohindra, Ritin and Patil, Amol N and Suri, Vikas and Sharma, Vishal and Sharma, Arun Kumar and Dutta, Usha},
title = {Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70470}
}
EUVIMED